Singapore state investor Temasek has led a $65-million Series D round in SQZ Biotechnologies Company (SQZ), a US-based clinical-stage cell therapy company, according to an announcement.
The round saw participation from GV, Illumina Ventures, Invus, JDRF T1D Fund, NanoDimension, and Polaris Partners.
